Friday, November 13, 2026

Enterprise AI spending shifts to production infrastructure as pilot phase ends globally

Global enterprises are moving AI deployments from experimental pilots to production systems, driving infrastructure investment across North America, Europe, and Asia. The Magnificent 7 tech companies raised 2026 AI infrastructure projections as financial services and regulated industries deploy customer-facing applications. Production requirements demand higher reliability, security certifications, and hybrid cloud capabilities.

ViaNews Editorial Team

February 26, 2026

Enterprise AI spending shifts to production infrastructure as pilot phase ends globally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Global enterprises are transitioning AI deployments from pilot projects to production systems, requiring infrastructure investments across North America, Europe, and Asia. The Magnificent 7 tech companies increased AI infrastructure spending projections for 2026.

Cisco is prioritizing production-scale deployments. "We're focused on helping customers move AI from experimentation to production, securely, at scale," said Jeremy Foster, Cisco executive. The shift reflects growing enterprise confidence after years of testing.

Intel's Justin Boitano described the infrastructure shift: "Enterprises are building AI factories that turn data into intelligence at scale during inference." These facilities require dedicated hardware optimized for production workloads rather than research environments.

Red Hat's Brian Stevens emphasized hybrid deployment needs: "The future of enterprise AI will be defined by its ability to operate autonomously across the hybrid cloud." Most global enterprises run workloads across on-premises data centers and multiple cloud providers.

Supermicro and Red Hat expanded hardware certification for AI infrastructure. "Supermicro has an extensive portfolio of Red Hat-certified systems dedicated to delivering AI infrastructure," said Vik Malyala, Supermicro executive. Certification ensures vendor support guarantees across regions.

Financial services shows production momentum globally. FIS launched AI-powered banking products in October 2025, moving beyond internal testing to customer applications. Banks worldwide deploy AI for fraud detection, customer service automation, and credit risk assessment.

Production deployments require different infrastructure than research: higher reliability standards, security compliance certifications, multi-region redundancy, and integration with existing enterprise systems. Vendors adapt products as experimental budgets convert to production spending across international markets.


Sources:
1 Yahoo Finance, "Agentic AI Foundation Welcomes 97 New Members As Demand for Open, Collaborative Agent Standardizatio" (February 24, 2026)
2 Yahoo Finance, "Village Farms announces 10 new product offerings in Netherlands" (January 13, 2026)
3 Globe Newswire, "Indiaspora Releases Groundbreaking Report ‘India and its Diaspora: Partners in Progress’, Highlighti" (March 23, 2026)
4 Globe Newswire, "Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Tria" (March 22, 2026)
5 Yahoo Finance, "Assessing ESAB (ESAB) Valuation After Recent Share Price Weakness" (March 22, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com